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Abstract 
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of 
chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can 
arise due to several host or tumor‑related factors. However, most current research is focused on tumor‑specific factors 
and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed 
types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in 
modifying drug resistance with respect to the treatment of cancer.
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Background
In US only, the newly diagnosed cancer patient is 
1,665,540 every year and the estimated death is 585,720 
[1] which are increasing as countries become more devel-
oped and more people reach advanced ages. Therefore, 
many efforts are being done in the war against cancer [2]. 
One of these efforts is the continuous development of 
new drugs and forms of chemotherapy.
In cancer, chemotherapy represents the backbone 
of treatment for many cancers at different stages of the 
disease. Therefore, chemotherapeutic resistance results 
in therapeutic failure and usually, (eventually) death. To 
address these limitations, many researchers focus on how 
cancer cells manipulate their genomes and metabolism 
to prevent drug influx and/or facilitate efflux of accumu-
lated drugs, the so called: “the neostrategy of cancer cells 
and tissues” [3]. In this work, we show that drug resist-
ance is a multifactorial phenomenon that requires atten-
tion to the host as well as the tumor and that such factors 
are organized at different levels (Figure 1).
Macroscopic (systemic) resistance [host–related 
factors]
One of the major effects of host-related factors that 
determine the activity of the drug is pharmacokinetic. 
Pharmacokinetics is defined as the action of the body in 
response to drug and can be divided into the following 
consecutive steps: Absorption, Distribution, Metabo-
lism and Excretion (ADME) [4]. Here we introduce the 
concept of “Pharmacokinetic Resistance” to describe the 
body-related factors that alter the effectiveness of the 
drug, so that it either does not reach its target and/or 
cannot accomplish its intended goal. Chemotherapeutics 
must be in contact with the tumor.
Absorption
There are growing evidences suggesting that orally can-
cer chemotherapy is preferable to intravenous admin-
istration, because: (1) it is low-cost from the national 
health services perspective (i.e. does not require hospi-
talisation), (2) it can increase the drug’s antitumor activ-
ity by prolonging it’s time to clearance [5], (3) it reduces 
drug toxicity [6], (4) increase patients’ compliance and 
improve pharmacoeconomic issues [7–9]. However, 
to maintain a sufficient amount of orally administered 
chemotherapeutics, several factors should be taken into 
consideration:
Open Access
*Correspondence:  Alfarouk@Hala‑Alfarouk.org 
1 Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
Full list of author information is available at the end of the article
Page 2 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
P‑gp
Permeability glycoprotein (P-gp), also known as multi-
drug drug resistance protein (MDR) is found along the 
gastrointestinal tract (GIT) [10], including the small 
intestine as primary site for the epithelial absorption of 
many orally administered drugs [11]. It has been shown 
that P-gp reduces the oral bioavailability of some anti-
cancer drugs [12]. Concomitant administration of some 
of the antineoplastic agents leads to the overexpression 
of P-gp that results in bioavailability reduction of several 
these agents, e.g. Imatinib [13]. P-gp expression, in the 
gut, is a subject of interindividual variation due to either 
genetic polymorphism or pathologic condition [14, 15] 
and so fluctuates the bioavailability of several antineo-
plastic agents e.g. paclitaxel [12].
Food
The effects of food on drug absorption and bioavailability 
have been attracting attention very much and stimulated 
a long debate of whether fasting improved or worsened 
a drug’s bioavailability [16–18]. It has been shown that 
the half-life period of orally applied Topotecan is longer 
than that of intravenous administration. The adminis-
tration of Topotecan with a high-fat breakfast shows a 
small decrease in the absorption rate but does not affect 
the extent of the absolute absorption [19]. St John’s 
wort, induces the expression of Pregnane X receptor, a 
xenobiotic or detoxification sensor, which reduces the 
efficacy of some antineoplastic agents, e.g. Irinotecan 
[4]. CYP3A4 is a metabolising enzyme (see below) which 
has been found in the intestine presumably as a defense 
strategy against xenobiotics [20]. It is well known that 
grapefruit juice abates the presence of CYP3A4, which is 
beneficial for the application of antineoplastic oral agents 
with low bioavailability [21]. Thus, it becomes apparent 
that the interaction between food and antineoplastic 
agents should be cautiously monitored to maintain a suf-
ficient bioavailability [22–24].
Distribution
The “volume of distribution” (Vd) of the drug is a hypo-
thetical volume that outlines drug distribution into tis-
sues [25, 26]. A higher Vd means that more of a drug 
penetrates into a tissue while it is more diluted (present 
at lower concentrations) in the plasma. The distribution 
of the drug between plasma and tissues relies on several 
factors. Some of them include:
1. Gender Metronidazole, a bactericide and protozoo-
cide, also displays a potential activity as an antican-
cer drug, especially as a radiosensitizer in hypoxic 
regions [27], and shows a lower Vd in women [28] 
Furthermore, women are subject to pharmacokinetic 
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Figure 1 Diagrammatic representation describes that cancer chemotherapy resistance is a multi‑factorial phenomenon that could be organized as 
multilevel structure.
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fore, it is critical to consider the gender factor also to 
age if the concentration of the drug in the plasma is 
to be determined or needs to be defined.
2. Weight Weight is a paramount factor that determines 
dose adjustment [30]. Cancer patients often lose 
weight during tumor progression [31–33]. Therefore, 
dosing based on body weight should be routinely re-
adjusted to the current weight [34, 35].
3. Plasma proteins when a drug is available in the blood 
(plasma), the drug will be found either in free or 
bound form to plasma proteins (see Figure 2). Albu-
min and Alpha 1-acid glycoprotein are an example of 
drug-binding plasma proteins. While albumin carries 
acidic drugs, the alpha 1-acid glycoprotein will carry 
basic and neutral lipophilic drugs [36–38].
• Albumin: Albumin is an important binding pro-
tein in the blood. It is a powerful prognostic indi-
cator reflecting diseases’ severity [39, 40], and its 
prognostic value is subject to gender differences 
[41]. It has been shown that etoposide is subject 
to individual variations (Population diversity) 
changes in the albumin serum concentration and/
or age [42, 43].
•  Alpha-1-acid glycoprotein (AGP or AAG) some-
times called orosomucoid (ORM) is an acute 
phase plasma alpha globulin glycoprotein. AGP 
is a critical determinant factor for the activity of 
several anticancer agents, e.g. imatinib [44]. Vari-
ation of AGP’s serum concentration also affects 
the anticancer activity of Gefitinib [45]. Wu et al. 
showed that the γ-secretase inhibitor RO4929097 
(Notch signaling blocker) is bound in plasma 
with high affinity to AGP and can be competi-
tively replaced by GDC-0449 (Hedgehog inhibi-
tor). This consequently increases the availability 
of potentially active RO4929097 [46]. Therefore, 
it was suggested that AGP monitoring is critical 
to predict the pharmacodynamics response to a 
combined RO4929097/GDC-0449 treatment [46].
4. Circadian rhythm The circadian timing system com-
prises peripheral oscillators located in most tissues 
of the body and a central pacemaker located in the 
suprachiasmatic nucleus (SCN) of the hypothalamus 
[47]. The circadian rhythm has been implicated in 
the pathophysiology of several diseases [48–50], drug 
action [51, 52] and pharmacokinetics of drugs as well 
[53–55]. Plasma protein levels reach their minimum 
around 4:00 a.m. and start to increase around 8:00 
a.m. [56]. This circadian rhythm can be masked at 
younger ages, but it aggravates and becomes clearer 
with aging [56]. Therefore, proper dosage timing 
should result in higher drug concentrations reaching 
the tumor site. It has been shown that alpha one acid 
glycoprotein (AGP) is subject to circadian rhythms 
[57]. In cancer, it has been demonstrated that Cis-
platinum shows a considerable variability in its bind-
ing capacity day and night [58, 59]. Thus, circadian 
rhythmicity has a significant impact on a drug’s phar-
macophore i.e. the active site of the drug molecule, 
and a delicate balancing between chronotolerability 
(minimum toxicity to host) and chronoefficacy (max-
imum cytotoxicity) is required [60]. Moreover, most 
of currently used anticancer agents act against highly 
proliferating cells, and since the basal metabolic rate 
is increased at night, it seems adequate to administer 
anticancer drugs at night instead of during the day.
Metabolism
Drug metabolism does not reflect the conventional met-
abolic pathways, i.e. anabolic for biomass or catabolism 
for energy production. Instead, drug metabolism involves 
changing drug polarity and thus its hydrophilicity, to 
facilitate its excretion from the body. Drug metabolism 
occurs through two steps: the first involves reactions 
such as hydroxylation or oxidation [61, 62] of lipophilic 
drugs to make it vulnerable to the addition of glutathione, 
glucouronic acid or an amino acid [63, 64]. Although it 
is generally accepted that drug metabolism is a biologi-
cal strategy of detoxification, some metabolism enzymes 
such as cytochrome P450 and glutathione S–transferase 
could be taken advantage of as they can activate certain 
anticancer drugs [65].
 – A group of cytochrome P450 (CYP) enzymes respon-
sible for the first step, the introduction of reactive 
or polar groups into xenobiotic groups [66]. CYP 
enzymes have been shown to activate some of the 
anticancer agents [67], as well as inactivate other anti-
cancer drugs [68]. Overexpression of CYP450 in can-
cer patients might lead to resistance due to the rapid 
inactivation of the drug. Moreover, the presence of 
CYP450 shows interindividual variation [69–71] and 
so its detection, identification, and quantification prior 
to starting treatment is essential.
  – Glutathione–S–Transferases (GSTs) are endogenous 
detoxifying enzymes [72] which mediate the second 
Figure 2 A drug is active while in unbound form. Therefore, the abil‑
ity of ‎the drug to bind plasma proteins and tissue reduces its activity 
[221], ‎The drug’s activity is modulated by ifferences in the amount of 
plasma ‎proteins [222–224]. ‎
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step of drug metabolism [73]. Overexpression of GST 
correlates with drug resistance [74–76]. This resistance 
could occur pharmacokinetically by metabolizing the 
drugs into inactive molecules [77]. Others suggest this 
resistance corresponds to detoxification via energy-
dependent, transporter-mediated efflux of drugs or 
drug conjugates from the cell [78]. Also, GST generates 
resistance by suppressing apoptosis through its ROS-
scavenging activity [79, 80] or via MAP kinase inhibi-
tion [81]. Conversely, GST is involved in the activation 
of certain drugs such as γ -Glutamyl- α -amino-(2- 
ethyl-N, N, N,N- tetrakis (2-chloroethyl) phosphoro-
diamidate)-sulfonyl-propionyl)-(R)-(-) phenylglycine 
(TER286) [65], 6-mercaptopurine (6-MP) [82], and 
TLK-286 [83]. Because GST shows variability in its 
expression across populations [84–87], GST detec-
tion prior to chemotherapy could be utilized to inform 
established therapeutic strategies. Potential GST 
inhibitors include ethacrynic acid and buthionine sul-
foximine [88]. These agents might be consumed con-
comitantly to keep GST in check in cancer and during 
cancer therapy. Interestingly, GST is subject to circa-
dian rhythmicity that also affects the activity of 5–fluo-
rouracil (5-FU) and Oxaliplatin [89–91].
  – Extrahepatic metabolism: Typically, the liver plays a major 
role in drug metabolism. Drug-metabolizing enzymes 
are also present at other sites e.g. lung, gut, kidney, uri-
nary bladder, skin [92–95]. Some of anticancer agent is a 
subjected into extrahepatic metabolism e.g. Oracin [95], 
and Paclitaxel could be subjected to extrahepatic metab-
olism too [96]. Extrahepatic metabolism also subjected 
to interindividual variation [95]. So, this issue should be 
addressed careful monitoring of these agents should dis-
cuss toward individualized chemotherapy [68, 97].
Excretion
Excretion from the body is the final step in drug removal. 
Commonly, excretion of drugs occurs through two main 
routes: biliary and renal excretion.
 – Biliary or bile duct excretion: MDR (ABC) mediates 
biliary excretion of xenobiotics [98]. Overexpression 
of ABC is correlated with an increase in biliary excre-
tion [99–102]. Therefore, careful monitoring of ABC 
expression should be taken into account when defined 
anticancer drug is prescribed for the patients and this 
anticancer drug is knowingly excreted through the bile.
  – Renal excretion: The kidney is the primary organ by 
which drugs are excreted. Interindividual renal drug 
excretion variability might be due to gender differences 
[103, 104] and ethnic differences [105]. So, changes in 
the glomerular filtration rate (GFR) have a direct effect 
on anticancer drug availability.
Drug–drug interactions
Cancer chemotherapy is administered in the form of a 
cocktail, the combined application of several chemother-
apeutics. Such a combination is designed to reduce toxic-
ity and to decrease the likelihood of resistance. One drug 
alone would require a higher concentration and, so the 
side effects caused would be increased. Using a combina-
tion reduces the side-effects of each single drug as it can 
be applied at a significantly lower concentration [106]. 
A tumor consists of a heterogeneous population and it 
is commonly thought that using a “cocktail” of several 
agents will target different populations and thus reduce 
the selective pressure by using single agents (the use of 
only one single agent might kill one defined population 
and positively select a pre-adapted one that will remain 
and grow). Therefore, a combination therapy is useful in 
treating cancer. Conversely, it needs to be pointed out 
that co-administration of drugs might result in antago-
nism such that one drug may counteract or neutralize 
another one:
 – Agents that target tumor vascularization: tumors 
require a blood supply for the provision of oxygen 
and nutrients [107], removal of metabolites [108] and 
to support metastasis [109]. It is widely assumed that 
administration of agents that target tumor vasculature 
(antiangiogenic therapy) eventually interrupts tumor 
progression. There are two classes of these agents (1) 
Angiogenesis inhibitors; they inhibit the tumor that 
has initiated the angiogenic process and (2) vascu-
lar disrupting agents that destruct the existing tumor 
vessels. Those agents might limit perfusion of cyto-
toxic drugs especially upon chronic administration 
[110]. Moreover, it is postulated that antiangiogenic 
therapy is useful in the management of resistance to 
chemotherapy [111], however, diminishing tumor vas-
cularization may accelerate the adaptation to hypoxia 
while increasing the necrotic zone by accumulation of 
metabolites and so worsen tumor prognosis [112]
  – NaHCO3 has been recently used systemically in the 
treatment of cancer [113]. It induces systemic alkalo-
sis. By elevation of urine pH, methotrexate excretion is 
greatly enhanced. Therefore, NaHCO3 modulates the 
pharmacokinetics of methotrexate [114].
  – Tamoxifen is a prodrug that needs to be metabolized 
to its active form by CYP2D6, CYP3A, CYP2B6 and 
CYP2C19 [115]. Some drugs, particularly from the 
group of selective serotonin reuptake inhibitors, inhibit 
CYP2D6 and so reduce the efficacy of Tamoxifen by 
decreasing amount of its active metabolites [116–118].
  – Pravastatin, an HMG-CoA reductase inhibitor, is cor-
related with biliary excretion [119, 120] as a substrate 
of P-gp [121]. Also, it induces P-gp expression as well 
Page 5 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
[122] and so may promote resistance to other com-
pounds.
Microscopic (local) resistance [tumor related 
factors]
The loss of ability of drugs to kill cancer cells could also 
be due to failure at the tumor site. Such disability could 
occur via several mechanisms. Some of them are:
Evolutionary resistance
Also termed biochemical resistance [123, 124], acquired 
resistance [66, 125], active resistance [126], or extrinsic 
resistance [127]. Evolutionary resistance is an ancient 
type of resistance that can be found in bacteria even prior 
exposure to antibiotics [128–132]. Evolutionary resist-
ance could occur either through interfering with drug 
resident time intracellularly and/or altering its site of 
action.
Alteration of drug residency in cancer cells
There are several proteins that alter drug residency in 
cancer cells. Some of these include:
P‑gp
P-glycoprotein 1 (permeability glycoprotein, abbrevi-
ated as P-gp or Pgp) also known as multidrug resistance 
protein 1 (MDR1) or ATP-binding cassette sub-family 
B member 1 (ABCB1) or cluster of differentiation 243 
(CD243). It is a glycoprotein that in humans is encoded 
by the ABCB1 gene [133, 134]. Commonly, P-gp is local-
ized at the plasma membrane [135] of colon, jejunum, 
bile canaliculi, renal tubular cells, placenta, the luminal 
surface of capillary endothelial cells, testes, pancreas and 
blood–brain barriers (BBB) [135–138]. P-gp might have 
a role in the normal secretion of metabolites. P-gp also 
induces expression of CYP3A4 [139] that in turn may 
deactivate some anticancer drugs (see Table 1 that shows 
the pharmacological modulators of P-gp).
In resistant cancer cell lines, P-gp is localized in the 
Golgi apparatus and the rough endoplasmic reticulum 
[140, 141]. Also, it is expressed in mitochondrial cristae 
[142, 143] to protect the accumulation of mitochondria 
[144] or prevent nuclear accumulation by expression of 
P-gp at the nuclear envelope [141, 145].
Expression of P-gp fluctuates with elevated expression 
level in untreated cancer into higher level upon relapse 
after chemotherapy and undetectable or low level in the 
expression in drug sensitive tumors [134, 146] which 
means there is no unifying theorem correlating expres-
sion of P-gp and cancer treatment.
MRPs Multidrug resistance-associated protein MRP1 
(ABCC1) was the first of the xenobiotic-transporting 
MRP-related proteins to be cloned and was identified 
based on its overexpression in a multidrug-resistant lung 
cancer cell line [147]. The MRP family consists of the four 
isoforms MRP1-4 [148, 149]. MRPs are similar to P-gp in 
that they are (I) capable of decreasing intracellular drug 
levels and (II) ATP-dependent [150]. Also, MRPs require 
glutathione GSH to extrude xenobiotics [151–154].
MXR The Mitoxantrone resistance protein MXR or the 
Multixenobiotic resistance protein, also known as BCRP, 
ABCP and ABCG2, is one member of the ABC-super-
family that plays a role in trafficking biological molecules 
across cell membranes [155]. Expression of MXR might 
be an alternative strategy of resistance if cancer cells lack 
p-gp and MRP [156]. MXR preferentially extrudes large 
hydrophobic, positively charged molecules while others 
members of the MRP family can eject both hydrophobic 
uncharged molecules and water-soluble anionic com-
pounds [157].
Alteration of drug target
When the drug reaches its target, another mechanism of 
resistance could be evolved somatically. Examples, which 
explain this mechanism of resistance, is:
 – Methotrexate is a drug of choice for the treatment of 
rheumatoid arthritis [158–160]. Moreover, its activ-
ity against several types of tumors has been shown. It 
inhibits tumor cells via inhibition of the Dihydrofolate 
reductase enzyme (DHFR) which is a co-enzyme in 
DNA-methylation. Both, in  vitro and in  vivo studies 
show that the genomic amplification of the DHFR gene 
is reflected by extra copies of DHFR [161–163].
  – 5-fluorouracil is a thymidylate synthetase inhibitor that 
is widely used in several types of tumors. Thymidylate 
Table 1 Shows the pharmacological modulators of P-gp
Inducers Inhibitor
Prazosin, Topotecan, Amprena [222], Rifampin, Phenobarbital,  
Clotrimazole, Reserpine, Isosafrole, Midazolam and Nifedipine [139, 223], 
Dexamethasone [224]
Morphine [225], Retinoic acid [226], St John’s wort [227]
Carvedilol [228], Cyclosporine [229], Itraconazole [230], Ketoconazole [231],
Synthetic opiates e.g. Meperidine, Methadone, Pentazocine [232], Tamox‑
ifen [233, 234], Vandetanib [235], β‑elemene [236]
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synthetase is an enzyme used to generate thymidine 
monophosphate, which is subsequently phosphoryl-
ated to thymidine triphosphate for use in DNA syn-
thesis and repair [164]. It has been postulated that one 
mechanism of resistance is the gain of extra copies of 
thymidylate synthetase genes [165, 166].
Microenvironmental resistance
Cancer cells maintain a unique pH gradient; it is more 
acidic extracellularly and more alkaline intracellularly 
about normal tissues [167–169]. Such a pH gradient 
creates a unique environment around cancer cells. The 
tumor microenvironment becomes one of the cancer’s 
hallmarks [109]. Tumor microenvironment increases 
tumor’s fitness by blunting the immune system [167, 
170], activating endogenous immunosuppressive strat-
egies [171] and inhibiting the growth of the normal cell 
population. Moreover, the tumor microenvironment 
disables the activities of several chemotherapeutic agents 
resulting in resistance and failure in drug response [172] 
either through disturbing drug partitioning, sequestering 
it intracellularly [173, 174] or through induction of MDR 
expression [146].
There are several components of the tumor microenvi-
ronment that contribute to drug disability. Some of them 
include:
pH
Most anticancer agents are either weak bases or weak 
acids. Some of them are Zwitterions (see Table  2). 
Weakly basic anticancer drugs are ionizable at the inter-
stitial fluid that decreases their partitioning, and if they 
cross the plasma membrane, they are sequestered into 
acidic vesicles (lysosomes). While weakly acid drugs 
increase their partitioning into the interstitial fluid, they 
will be rendered at cytosol due to intracellular alkalin-
ity, and so they are slightly prevented from reaching their 
targets. This phenomenon is well known as “ion trapping 
mechanism” [123, 124, 175–177]. While basic drugs have 
reduced efficacy in an acidic microenvironment, Chlo-
rambucil is a weakly acidic compound, and its cytotox-
icity is enhanced by acidic microenvironments [178]. So, 
any attempt to induce intracellular acidification could be 
an avenue to both breaking through MDR and as an anti-
cancer therapeutic approach it own [179].
Oxygen
Intermittent hypoxia has been considered a suggested 
mechanism for the initiation of carcinogenesis [180–183] 
tumor evolution and progression [184–186] and metas-
tasis [187].
Hypoxia somehow handles drug resistance via the fol-
lowing factors:
1. Most anticancer agents act to activate the apoptosis 
pathway, and the presence of free radicals are essen-
tial to promote this process [188]. Therefore, the 
absence of oxygen will diminish the activity of these 
drugs. Hypoxia does not only confer resistance to 
chemotherapy [189–192] but also to radiation [27].
2. Hypoxia induces genes expression that code for 
ABC-transporters [193] and so favors the developing 
of resistance of some of the anticancer drugs e.g. 5–
fluorouracil [194].
3. Hypoxia also alters activity of some of metaboliz-
ing enzymes that are responsible for the activa-
tion and/or inactivation of some of the anticancer 
drugs e.g. conversion of paclitaxel metabolism into 
6-α-hydroxypaclitaxel is reduced upon hypoxic con-
ditions compared to normoxic conditions in HepaRG 
cells [195]. Therefore, hypoxia might alter therapeutic 
effectiveness.
4. Hypoxia is an important evolutionary determinant 
factor that shapes part of the tumor population to 
become hypoxia-adapted [108]. Hypoxia is associ-
ated with cellular senescence [196]. Chemotherapeu-
tic agents which are designed to target cells that have 
high proliferation rates will fail even if they reach 
their site of action in sufficient amounts in poorly 
vascularized regions [197, 198]. Conversely, recent 
data suggests that hypoxia suppresses geroconversion 
(the conversion of arrested cells to senescence) [199] 
which make the role of hypoxia in tumorigenesis and 
tumor resistance still unclear.
Glucose
In the 1920s, Otto Warburg discovered that cancer have 
high aerobic glycolysis even in the presence of oxygen 
[200–202]. Recently, metabolic reprogramming of cancer 
has been adopted as one of the hallmarks of cancer [109]. 
Table 2 Shows pKa of some of commonly used anticancer 
agents
* Although the pKa of 5-FU is higher but it considered as weak acid due to 
electrons withdrawn capacity due to Fluorine atom [124].
Drugs pKa Ionization behavior
Daunorubicin 8.3 Weak base
Doxorubicin 8.3 Weak base
Mitoxantrone 8.3 Weak base
Paclitaxel Zwitterion
5‑Fluorouracil 7.76* Weak acid
Cyclophosphamide ‎6.0‎ Weak acid
Chlorambucil 5.8 Weak acid
Cisplatin 5.06 Weak acid
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Glucose, especially in high loads, induces over-expres-
sion of Sodium Hydrogen Exchanger 1 (NHE-1) resulting 
in the alkalinization of pHi [203] and in the induction of 
the metabolic transformation that aggravates the tumor 
microenvironment [27]. Moreover, glucose uptake is 
associated with tumor progression [204] as well as chem-
otherapeutic resistance [205]. Therefore, alteration of 
glucose transport [206], glucose deprivation, and fasting 
may enhance tumor sensitivity to chemotherapy [207]. 
However, targeting glucose also leads to interconversion 
of sensitive populations into more resistant populations, 
which may handle relapse [208]. So, targeting glucose as 
a potential strategy for overcoming resistance may be a 
dead end.
Mesoscopic (physical, mechanical) or (regional) 
resistance [tumor—host interacting factors]
The physics of the tumor site has a great impact on drug 
activity and results in drug resistance as follows:
1. Geometric, or vascular, resistance is a complex func-
tion of vascular morphology, i.e. the number of ves-
sels of various types, their branching pattern, their 
diameter, and length [209]. It has been showing that 
upon clonal tumor expansion, tumor perfusion, and, 
therefore, the amount of drug to reaching its target 
is decreased [198, 210, 211]. Vascular modulating 
agents may alter vascular resistance and diminish the 
drugs reaching their targets [212] while by reducing 
the geometric resistance will enhance the activity of 
chemotherapeutic agents [213].
2. Blood viscosity is very significant especially for intra-
tumoral blood flow [209]. Highly blood viscosity is 
an indicator for blood stasis and thus for the stag-
nation of drugs at certain sites. Moreover, inflamma-
tory mediators at tumor sites might alter erythrocyte 
sedimentation rate and lead to greatly enhanced 
blood viscosity [214], at least at the tumor. Because 
blood flow has been correlated with oxygen diffu-
sion kinetics [215], increasing blood viscosity may 
induces blood flow retardation and hypoxia becomes 
an adaptive strategy of survival especially for xeric 
phenotypes (cancer cells that grow distal from blood 
vessels) [108]. This also contributes to drug penetra-
tion into intratumor regions (see Figure 3). Anemia 
also might occur due reduction in hematocrit. In 
this regard, bone marrow suppression by chemo-
therapeutic agents should be taken into considera-
tion.
Co‑resistance
The presence of the extracellular matrix (ECM) and a 
stroma are crucial for carcinogenesis. Both of this play 
a significant role in cancer progression, metabolism and 
the metastatic cascade [216]. In this context, the ECM 
plays a critical role in mediating drug resistance [217], 
either by acting as a physical barrier that impairs drug 
diffusion [218] and/or by cooperating with tumor cells 
to generate chemotherapy resistance [219, 220]. In this 
regard, this strategy of resistance could be called ECM-
dependent resistance [220, 221].
Conclusions
From bacteria to cancer, (multi) drug resistance is becom-
ing a central issue and a significant challenge for medicine 
today. Although drug resistance is often studied at the sin-
gle cell level, it is important to realize that the ability of 
a drug to interact with its target is more complex involv-
ing many body compartments. Also, over the past decade, 
there have been significant changes in our understanding 
of some fields from biology. Whereas, before, the key-
lock model was supposed to uncover biology helping us 
to understand life, it is clear today that evolution theory 
needs to be introduced at the single cell level to clarify 
our understanding of some diseases including cancer. The 
famous key-lock model, as well as the long-awaited magic 
bullet to kill cancer, has to be revised accordingly. There-
fore, we suggest reframing the concepts used in drug 
resistance in a more general context thereby dismantling 
the monolithic tone that the resistance is only a matter of 
genes. We propose that drug ineffectiveness results from 
tumor-host interactions and that a clear understanding of 
Figure 3 A hypothetical model describes the sphenoid tumor as 
mutli‑‎habitat or multilayer shows that decrease of oxygen diffusion 
with drug gradients as a function of distance from the blood vessel.‎
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such an interaction open new opportunities not only for 
the discovery of new drugs but also for new therapeutic 
strategies to overcome the development and evolution of 
resistance to cancer chemotherapy.
Compliance with ethical guidelines
Competing interests The authors declare that they have no competing 
interests.
Author details
1 Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. 
2 University of Münster, Münster, Germany. 3 School of Veterinary Medicine 
and Science, University of Nottingham, Nottingham, UK. 4 Faculty of Pharmacy, 
University of Khartoum, Khartoum, Sudan. 5 H. Lee Moffitt Cancer Center, 
Tampa, FL, USA. 6 King Saud University, Riyadh, Kingdom of Saudi Arabia.  
7 Uneizah Pharmacy College, Qassim University, AL‑Qassim, Kingdom of Saudi 
Arabia. 8 Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan. 
9 Institute of Clinical Biology and Metabolism, Vitoria, Spain. 10 Department 
of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, 
Italy. 
Received: 26 January 2015   Accepted: 30 June 2015
References
 1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J 
Clin 64:9–29
 2. Gatenby RA (2009) A change of strategy in the war on cancer. Nature 
459:508–509
 3. Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ (2005) The 
role of pH dynamics and the Na+/H+ antiporter in the etiopathogen‑
esis and treatment of cancer. Two faces of the same coin–one single 
nature. Biochim Biophys Acta 1756:1–24
 4. Undevia SD, Gomez‑Abuin G, Ratain MJ (2005) Pharmacokinetic vari‑
ability of anticancer agents. Nat Rev Cancer 5:447–458
 5. Paxton JW (1986) The effect of food on the bioavailability and kinetics 
of the anticancer drug amsacrine and a new analogue, N‑5‑dimethyl‑
9‑[(2‑methoxy‑4‑methylsulphonylamino)phenylamino]‑4 acridinecar‑
boxamide in rabbits. J Pharm Pharmacol 38:837–840
 6. McLeod HL, Evans WE (1999) Oral cancer chemotherapy: the promise 
and the pitfalls. Clin Cancer Res 5:2669–2671
 7. DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future 
directions. J Clin Oncol 16:2557–2567
 8. Fujiwara Y (1999) Current status of oral anticancer drugs in Japan. J Clin 
Oncol 17:3362–3365
 9. Sharma S (2001) Patient selection for oral chemotherapy. Oncology 
(Williston Park) 15(1 Suppl 2):33–35
 10. Thörn M, Finnström N, Lundgren S, Rane A, Lööf L (2005) Cytochromes 
P450 and MDR1 mRNA expression along the human gastrointestinal 
tract. Br J Clin Pharmacol 60:54–60
 11. Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic 
drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 
46:89–102
 12. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer 
DKF et al (1997) Limited oral bioavailability and active epithelial excre‑
tion of paclitaxel (Taxol) caused by P‑glycoprotein in the intestine. Proc 
Natl Acad Sci USA 94:2031–2035
 13. Burger H, Nooter K (2004) Pharmacokinetic resistance to imatinib 
mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 
(MDR1) in the oral bioavailability of imatinib. Cell Cycle 3:1502–1505
 14. Dietrich CG, Geier A, Oude Elferink RPJ (2003) ABC of oral bioavailability: 
transporters as gatekeepers in the gut. Gut 52:1788–1795
 15. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al 
(2001) Frequency of single nucleotide polymorphisms in the P‑glyco‑
protein drug transporter MDR1 gene in white subjects. Clin Pharmacol 
Ther 69:169–174
 16. Ling J, Fettner S, Lum BL, Riek M, Rakhit A (2008) Effect of food on the 
pharmacokinetics of erlotinib, an orally active epidermal growth factor 
receptor tyrosine‑kinase inhibitor, in healthy individuals. Anticancer 
Drugs 19:209–216
 17. Jain RK, Brar SS, Lesko LJ (2010) Food and oral antineoplastics: more 
than meets the eye. Clin Cancer Res 16:4305–4307
 18. Kang SP, Ratain MJ (2010) Inconsistent labeling of food effect for oral 
agents across therapeutic areas: differences between oncology and 
non‑oncology products. Clin Cancer Res 16:4446–4451
 19. Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batch‑
elor D, Doyle E (1999) Oral topotecan: bioavailablity and effect of food 
co‑administration. Br J Cancer 80:1380–1386
 20. Kivistö KT, Niemi M, Fromm MF (2004) Functional interaction of intesti‑
nal CYP3A4 and P‑glycoprotein. Fundam Clin Pharmacol 18:621–626
 21. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF (1998) 
Inactivation of cytochrome P450 3A4 by bergamottin, a component of 
grapefruit juice. Chem Res Toxicol 11:252–259
 22. Fujita K (2004) Food‑drug interactions via human cytochrome P450 3A 
(CYP3A). Drug Metabol Drug Interact 20:195–217
 23. Singh BN, Malhotra BK (2004) Effects of food on the clinical 
pharmacokinetics of anticancer agents: underlying mechanisms 
and implications for oral chemotherapy. Clin Pharmacokinet 
43:1127–1156
 24. Ruggiero A, Cefalo MG, Coccia P, Mastrangelo S, Maurizi P, Riccardi R 
(2012) The role of diet on the clinical pharmacology of oral antineoplas‑
tic agents. Eur J Clin Pharmacol 68:115–122
 25. Wilson K (1984) Sex‑related differences in drug disposition in man. Clin 
Pharmacokinet 9:189–202
 26. Pleym H, Spigset O, Kharasch ED, Dale O (2003) Gender differences 
in drug effects: implications for anesthesiologists. Acta Anaesthesiol 
Scand 47:241–259
 27. Alfarouk KO, Shayoub MEAA, Muddathir AK, Elhassan GO, Bashir AHHH 
(2011) Evolution of tumor metabolism might reflect carcinogenesis as 
a reverse evolution process (dismantling of multicellularity). Cancers 
(Basel) 3:3002–3017
 28. Soldin OP, Chung SH, Mattison DR (2011) Sex differences in drug dispo‑
sition. J Biomed Biotechnol 2011:187103
 29. Beierle I, Meibohm B, Derendorf H (1999) Gender differences in 
pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 
37:529–547
 30. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the 
pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87
 31. Theologides A (1977) Nutritional management of the patient with 
advanced cancer. Postgrad Med 61:97–101
 32. Fearon KC (1992) The Sir David Cuthbertson Medal Lecture 1991. The 
mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 
51:251–265
 33. Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: 
effect of weight loss, reduced food intake, and systemic inflammation 
on functional status and prognosis. Am J Clin Nutr 83:1345–1350
 34. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on 
the pharmacokinetics of cyclophosphamide in breast cancer patients. 
Cancer Chemother Pharmacol 20:219–222
 35. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anti‑
cancer drugs: the good, the bad and body‑surface area. Eur J Cancer 
38:1677–1684
 36. Tillement JP, Zini R, d’ Athis P, Vassent G (1974) Binding of certain acidic 
drugs to human albumin: theoretical and practical estimation of funda‑
mental parameters. Eur J Clin Pharmacol 7:307–313
 37. Ruiz‑Cabello F, Erill S (1984) Abnormal serum protein binding of acidic 
drugs in diabetes mellitus. Clin Pharmacol Ther 36:691–695
 38. Routledge PA (1986) The plasma protein binding of basic drugs. Br J 
Clin Pharmacol 22:499–506
 39. Goldwasser P, Feldman J (1997) Association of serum albumin and 
mortality risk. J Clin Epidemiol 50:693–703
 40. Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA (2003) Is serum albumin 
an independent predictor of survival in patients with breast cancer? 
JPEN J Parenter Enteral Nutr 27:10–15
 41. Grimm G, Haslacher H, Kampitsch T, Endler G, Marsik C, Schickbauer T 
et al (2009) Sex differences in the association between albumin and 
all‑cause and vascular mortality. Eur J Clin Invest 39:860–865
Page 9 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
 42. Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ (1995) Etoposide protein bind‑
ing in cancer patients. Cancer Chemother Pharmacol 36:506–512
 43. Liliemark E, Söderhäll S, Sirzea F, Gruber A, Osby E, Björkholm M et al 
(1996) Higher in vivo protein binding of etoposide in children com‑
pared with adult cancer patients. Cancer Lett 106:97–100
 44. Gambacorti‑Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, 
Bungaro S et al (2003) Alpha1 acid glycoprotein binds to imatinib 
(STI571) and substantially alters its pharmacokinetics in chronic myeloid 
leukemia patients. Clin Cancer Res 9:625–632
 45. Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD (2006) Binding 
of gefitinib, an inhibitor of epidermal growth factor receptor‑tyrosine 
kinase, to plasma proteins and blood cells: in vitro and in cancer 
patients. Invest New Drugs 24:291–297
 46. Wu J, Lorusso PM, Matherly LH, Li J (2012) Implications of plasma 
protein binding for pharmacokinetics and pharmacodynamics of the 
γ‑secretase inhibitor RO4929097. Clin Cancer Res 18:2066–2079
 47. Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeu‑
tic implications. Annu Rev Pharmacol Toxicol 47:593–628
 48. Sukumaran S, Almon RR, DuBois DC, Jusko WJ (2010) Circadian rhythms 
in gene expression: relationship to physiology, disease, drug disposition 
and drug action. Adv Drug Deliv Rev 62:904–917
 49. Takahashi JS, Hong H‑K, Ko CH, McDearmon EL (2008) The genetics of 
mammalian circadian order and disorder: implications for physiology 
and disease. Nat Rev Genet 9:764–775
 50. Rana S, Mahmood S (2010) Circadian rhythm and its role in malignancy. 
J Circadian Rhythms 8:3
 51. Straub RH, Cutolo M (2007) Circadian rhythms in rheumatoid arthritis: 
implications for pathophysiology and therapeutic management. Arthri‑
tis Rheum 56:399–408
 52. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) 
Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 
50:377–421
 53. Prémaud A, Rousseau A, Gicquel M, Ragot S, Manceau J, Laurentie M 
et al (2002) An animal model for the study of chronopharmacokinetics 
of drugs and application to methotrexate and vinorelbine. Toxicol Appl 
Pharmacol 183:189–197
 54. Baraldo M (2008) The influence of circadian rhythms on the kinetics of 
drugs in humans. Expert Opin Drug Metab Toxicol 4:175–192
 55. Erkekoglu P, Baydar T (2012) Chronopharmacokinetics of drugs in 
toxicological aspects: a short review for pharmacy practitioners. J Res 
Pharm Pract 1:3–9
 56. Touitou Y, Touitou C, Bogdan A, Reinberg A, Auzeby A, Beck H et al (1986) 
Differences between young and elderly subjects in seasonal and circa‑
dian variations of total plasma proteins and blood volume as reflected by 
hemoglobin, hematocrit, and erythrocyte counts. Clin Chem 32:801–804
 57. Bruguerolle B, Arnaud C, Levi F, Focan C, Touitou Y, Bouvenot G (1989) 
Physiopathological alterations of alpha 1 acid glycoprotein temporal 
variations: implications for chronopharmacology. Prog Clin Biol Res 
300:199–214
 58. Hecquet B, Meynadier J, Bonneterre J, Adenis L, Demaille A (1985) Time 
dependency in plasmatic protein binding of cisplatin. Cancer Treat Rep 
69:79–83
 59. Hecquet B, Sucche M (1986) Theoretical study of the influence of the 
circadian rhythm of plasma protein binding on cisplatin area under the 
curve. J Pharmacokinet Biopharm 14:79–93
 60. Lévi F (2006) Chronotherapeutics: the relevance of timing in cancer 
therapy. Cancer Causes Control 17:611–621
 61. Guengerich FP (2007) Mechanisms of cytochrome P450 substrate 
oxidation: MiniReview. J Biochem Mol Toxicol 21:163–168
 62. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. 
Chem Res Toxicol 21:70–83
 63. Jancova P, Anzenbacher P, Anzenbacherova E (2010) Phase II drug 
metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc 
Czech Repub 154:103–116
 64. Gonzalez FJ (2006) Goodman and Gilman’s Pharmacological Basis of 
Therapeutics. In: Brunton LLLL, Lazo JS (eds) The McGraw‑Hill Compa‑
nies, Inc‎, New York, pp ‎71–92‎
 65. Rooseboom M, Commandeur JNM, Vermeulen NPE (2004) Enzyme‑
catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53–102
 66. Akhdar H, Legendre C, Caroline Aninat FM (2012) Topics on drug 
metabolism‎. In: Paxton J (ed) INTECH, pp ‎137–170‎
 67. McFadyen MCE, Melvin WT, Murray GI (2004) Cytochrome P450 enzymes: 
novel options for cancer therapeutics. Mol Cancer Ther 3:363–371
 68. Rodriguez‑Antona C, Ingelman‑Sundberg M (2006) Cytochrome P450 
pharmacogenetics and cancer. Oncogene 25:1679–1691
 69. Lin JH, Lu AY (2001) Interindividual variability in inhibition and induc‑
tion of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 
41:535–567
 70. Ingelman‑Sundberg M, Sim SC, Gomez A, Rodriguez‑Antona C (2007) 
Influence of cytochrome P450 polymorphisms on drug therapies: 
pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol 
Ther 116:496–526
 71. Plant N (2007) The human cytochrome P450 sub‑family: transcriptional 
regulation, inter‑individual variation and interaction networks. Biochim 
Biophys Acta 1770:478–488
 72. Hayes JD, Pulford DJ (1995) The glutathione S‑transferase supergene 
family: regulation of GST and the contribution of the isoenzymes to 
cancer chemoprotection and drug resistance. Crit Rev Biochem Mol 
Biol 30:445–600
 73. Xu C, Li CY‑T, Kong A‑NT (2005) Induction of phase I, II and III drug 
metabolism/transport by xenobiotics. Arch Pharm Res 28:249–268
 74. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J et al 
(1990) Glutathione‑S‑transferase pi as a determinant of drug resistance 
in transfectant cell lines. J Biol Chem 265:4296–4301
 75. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R (1997) 
Overexpression of resistance‑related proteins (metallothioneins, glu‑
tathione‑S‑transferase pi, heat shock protein 27, and lung resistance‑
related protein) in osteosarcoma. Relationship with poor prognosis. 
Cancer 79:2336–2344
 76. Harkey MA, Czerwinski M, Slattery J, Kiem H‑P (2005) Overexpression of 
glutathione‑S‑transferase, MGSTII, confers resistance to busulfan and 
melphalan. Cancer Invest 23:19–25
 77. Kauvar LM, Morgan AS, Sanderson PE, Henner WD (1998) Glutathione 
based approaches to improving cancer treatment. Chem Biol Interact 
111–112:225–238
 78. Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ et al (2005) 
Cancer chemotherapy and drug metabolism. Drug Metab Dispos 
33:1083–1096
 79. Kodym R, Calkins P, Story M (1999) The cloning and characterization of a 
new stress response protein. A mammalian member of a family of theta 
class glutathione s‑transferase‑like proteins. J Biol Chem 274:5131–5137
 80. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O’Brien PJ, Buchwald 
M (2001) Fanconi anemia group C protein prevents apoptosis in hemat‑
opoietic cells through redox regulation of GSTP1. Nat Med 7:814–820
 81. Townsend DM, Tew KD (2003) The role of glutathione‑S‑transferase in 
anti‑cancer drug resistance. Oncogene 22:7369–7375
 82. Gunnarsdottir S, Elfarra AA (1999) Glutathione‑dependent metabolism 
of cis‑3‑(9H‑purin‑6‑ylthio)acrylic acid to yield the chemotherapeutic 
drug 6‑mercaptopurine: evidence for two distinct mechanisms in rats. J 
Pharmacol Exp Ther 290:950–957
 83. Tew KD (2005) TLK‑286: a novel glutathione S‑transferase‑activated 
prodrug. Expert Opin Investig Drugs 14:1047–1054
 84. Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS 
et al (1995) Ethnic differences in the prevalence of the homozygous 
deleted genotype of glutathione S‑transferase theta. Carcinogenesis 
16:1243–1245
 85. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM (1996) Glutathione 
S‑transferase GSTM1 and GSTT1 null genotypes as potential risk factors 
for urothelial cancer of the bladder. Arch Toxicol 71:123–126
 86. LA Magno V, Talbot J, Talbot T, Borges Santos AM, Souza RP, Marin LJ 
(2009) Glutathione s‑transferase variants in a brazilian population. 
Pharmacology 83:231–236
 87. Ying X‑J, Dong P, Shen B, Xu C‑Z, Xu H‑M, Zhao S‑W (2012) Glutathione 
S‑transferase M1 gene polymorphism and laryngeal cancer risk: a meta‑
analysis. PLoS One 7:e42826
 88. Liu J, Chen H, Miller DS, Saavedra JE, Keefer LK, Johnson DR et al (2001) 
Overexpression of glutathione S‑transferase II and multidrug resistance 
transport proteins is associated with acquired tolerance to inorganic 
arsenic. Mol Pharmacol 60:302–309
 89. Lévi F, Altinok A, Clairambault J, Goldbeter A (2008) Implications of 
circadian clocks for the rhythmic delivery of cancer therapeutics. Philos 
Trans A Math Phys Eng Sci 366:3575–3598
Page 10 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
 90. Zeng Z‑L, Sun J, Guo L, Li S, Wu M, Qiu F et al (2005) Circadian rhythm 
in dihydropyrimidine dehydrogenase activity and reduced glutathione 
content in peripheral blood of nasopharyngeal carcinoma patients. 
Chronobiol Int 22:741–754
 91. Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF (2002) Rhythms in 
human bone marrow and blood cells. Chronobiol Int 19:101–127
 92. Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. 
Clin Pharmacokinet 26:144–160
 93. Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB 
(1988) Tissue distribution of drug‑metabolizing enzymes in humans. 
Xenobiotica 18:849–856
 94. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA (2001) The role of 
hepatic and extrahepatic UDP‑glucuronosyltransferases in human drug 
metabolism. Drug Metab Rev 33:273–297
 95. Ritter JK (2007) Intestinal UGTs as potential modifiers of pharmacoki‑
netics and biological responses to drugs and xenobiotics. Expert Opin 
Drug Metab Toxicol 3:93–107
 96. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al 
(2001) Polymorphisms in human CYP2C8 decrease metabolism of the 
anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 
11:597–607
 97. Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA 
et al (2009) Pharmacogenetic studies of Paclitaxel in the treatment of 
ovarian cancer. Basic Clin Pharmacol Toxicol 104:130–137
 98. Kusuhara H, Sugiyama Y (2002) Role of transporters in the tissue‑selec‑
tive distribution and elimination of drugs: transporters in the liver, small 
intestine, brain and kidney. J Control Release 78:43–54
 99. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD et al 
(2001) ABCA1 overexpression leads to hyperalphalipoproteinemia and 
increased biliary cholesterol excretion in transgenic mice. J Clin Invest 
108:303–309
 100. Yu L, Li‑Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC et al 
(2002) Overexpression of ABCG5 and ABCG8 promotes biliary choles‑
terol secretion and reduces fractional absorption of dietary cholesterol. 
J Clin Invest 110:671–680
 101. Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Elferink RPJO, 
Lagas JS et al (2006) Carcinogen and anticancer drug transport by Mrp2 
in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp 
Ther 318:319–327
 102. Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R et al 
(2004) Hepatic overexpression of murine Abcb11 increases hepa‑
tobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem 
279:2790–2799
 103. Vree TB, Van Ewijk‑Beneken Kolmer EW, Wuis EW, Hekster YA, Broekman 
MM (1993) Interindividual variation in the capacity‑limited renal glucu‑
ronidation of probenecid by humans. Pharm World Sci 15:197–202
 104. Morris ME, Lee H‑J, Predko LM (2003) Gender differences in the 
membrane transport of endogenous and exogenous compounds. 
Pharmacol Rev 55:229–240
 105. Johnson JA (2000) Predictability of the effects of race or ethnicity on 
pharmacokinetics of drugs. Int J Clin Pharmacol Ther 38:53–60
 106. Loadman PM, Bibby MC (1994) Pharmacokinetic drug interactions with 
anticancer drugs. Clin Pharmacokinet 26:486–500
 107. Siemann DW (2006) Tumor vasculature : a target for anticancer thera‑
pies. In: Vascular‑targeted therapies in oncology. John Wiley & Sons, Ltd, 
Chichester, pp 1–8
 108. Alfarouk KO, Ibrahim ME, Gatenby RA, Brown JS (2013) Riparian ecosys‑
tems in human cancers. Evol Appl 6:46–53
 109. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next genera‑
tion. Cell 144:646–674
 110. Ma J, Waxman DJ (2008) Combination of antiangiogenesis with 
chemotherapy for more effective cancer treatment. Mol Cancer Ther 
7:3670–3684
 111. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitiza‑
tion strategy for cancer? Science 312:1171–1175
 112. Lloyd MC, Alfarouk KO, Verduzco D, Bui MM, Gillies RJ, Ibrahim ME et al 
(2014) Vascular measurements correlate with estrogen receptor status. 
BMC Cancer 14:279
 113. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF 
et al (2009) Bicarbonate increases tumor pH and inhibits spontaneous 
metastases. Cancer Res 69:2260–2268
 114. Lippens RJ (1984) Methotrexate. I. Pharmacology and pharmacokinet‑
ics. Am J Pediatr Hematol Oncol 6:379–395
 115. Singh MS, Francis PA, Michael M (2011) Tamoxifen, cytochrome P450 
genes and breast cancer clinical outcomes. Breast 20:111–118
 116. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al 
(2003) Active tamoxifen metabolite plasma concentrations after coad‑
ministration of tamoxifen and the selective serotonin reuptake inhibitor 
paroxetine. J Natl Cancer Inst 95:1758–1764
 117. Caraci F, Crupi R, Drago F, Spina E (2011) Metabolic drug interactions between 
antidepressants and anticancer drugs: focus on selective serotonin reup‑
take inhibitors and hypericum extract. Curr Drug Metab 12:570–577
 118. Yap KYL, Tay WL, Chui WK, Chan A (2011) Clinically relevant drug 
interactions between anticancer drugs and psychotropic agents. Eur J 
Cancer Care (Engl) 20:6–32
 119. Yamazaki M, Suzuki H, Sugiyama Y (1996) Recent advances in carrier‑
mediated hepatic uptake and biliary excretion of xenobiotics. Pharm 
Res 13:497–513
 120. König J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps 
of the multidrug resistance protein (MRP) family: localization, substrate 
specificity, and MRP2‑mediated drug resistance. Biochim Biophys Acta 
1461:377–394
 121. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y (2005) Bile salt 
export pump (BSEP/ABCB11) can transport a nonbile acid substrate, 
pravastatin. J Pharmacol Exp Ther 314:876–882
 122. Kamisako T, Ogawa H (2004) Effects of pravastatin and bezafibrate on 
biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in 
the rat. J Gastroenterol Hepatol 19:879–883
 123. Raghunand N, Martínez‑Zaguilán R, Wright SH, Gillies RJ (1999) pH and 
drug resistance. II. Turnover of acidic vesicles and resistance to weakly 
basic chemotherapeutic drugs. Biochem Pharmacol 57:1047–1058
 124. Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, 
ion trapping and chemotherapeutics. I. Acid pH affects the distribution 
of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218
 125. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu 
Rev Med 53:615–627
 126. Stewart DJ (2007) Saturable passive resistance in chemotherapy of 
epithelial maligancies. In: Parsons RA (ed) Progress in cancer drug resist‑
ance research. Nova Science, New York, pp ‎29–41‎
 127. De Visser KE, Jonkers J (2009) Towards understanding the role of 
cancer‑associated inflammation in chemoresistance. Curr Pharm Des 
15:1844–1853
 128. Barlow M, Hall BG (2002) Phylogenetic analysis shows that the OXA 
β‑lactamase genes have been on plasmids for millions of years. J Mol 
Evol 55:314–321
 129. Hall BG, Barlow M (2004) Evolution of the serine beta‑lactamases: past, 
present and future. Drug Resist Updat 7:111–123
 130. Baltz RH (2008) Renaissance in antibacterial discovery from actinomy‑
cetes. Curr Opin Pharmacol 557–563
 131. D’Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C et al 
(2011) Antibiotic resistance is ancient. Nature 477:457–461
 132. Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston 
MD et al (2012) Antibiotic resistance is prevalent in an isolated cave 
microbiome. PLoS One 7:e34953
 133. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1987) 
The human multidrug resistance (mdr1) gene. cDNA cloning and 
transcription initiation. J Biol Chem 262:505–508
 134. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A et al (1989) 
Expression of a multidrug resistance gene in human cancers. J Natl 
Cancer Inst 81:116–124
 135. Zhou S‑F (2008) Structure, function and regulation of P‑glycoprotein 
and its clinical relevance in drug disposition. Xenobiotica 38:802–832
 136. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham 
MC (1987) Cellular localization of the multidrug‑resistance gene prod‑
uct P‑glycoprotein in normal human tissues. Proc Natl Acad Sci USA 
84:7735–7738
 137. Schinkel A (1999) P‑Glycoprotein, a gatekeeper in the blood‑brain bar‑
rier. Adv Drug Deliv Rev 36:179–194
 138. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, 
Schinkel AH et al (2001) Subcellular localization and distribution of the 
breast cancer resistance protein transporter in normal human tissues. 
Cancer Res 61:3458–3464
Page 11 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
 139. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD (1996) P‑glycoprotein: 
a major determinant of rifampicin‑inducible expression of cytochrome 
P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001–4005
 140. Munteanu E, Verdier M, Grandjean‑Forestier F, Stenger C, Jayat‑Vignoles 
C, Huet S et al (2006) Mitochondrial localization and activity of 
P‑glycoprotein in doxorubicin‑resistant K562 cells. Biochem Pharmacol 
71:1162–1174
 141. Bendayan R, Ronaldson PT, Gingras D, Bendayan M (2006) In situ locali‑
zation of P‑glycoprotein (ABCB1) in human and rat brain. J Histochem 
Cytochem 54:1159–1167
 142. Solazzo M, Fantappiè O, D’Amico M, Sassoli C, Tani A, Cipriani G et al 
(2009) Mitochondrial expression and functional activity of breast cancer 
resistance protein in different multiple drug‑resistant cell lines. Cancer 
Res 69:7235–7242
 143. Shen Y, Chu Y, Yang Y, Wang Z (2012) Mitochondrial localization of 
P‑glycoprotein in the human breast cancer cell line MCF‑7/ADM and its 
functional characterization. Oncol Rep 27:1535–1540
 144. Solazzo M, Fantappiè O, Lasagna N, Sassoli C, Nosi D, Mazzanti R (2006) 
P‑gp localization in mitochondria and its functional characterization in 
multiple drug‑resistant cell lines. Exp Cell Res 312:4070–4078
 145. Babakhanian K, Bendayan M, Bendayan R (2007) Localization of P‑glyco‑
protein at the nuclear envelope of rat brain cells. Biochem Biophys Res 
Commun 361:301–306
 146. Wei LY, Roepe PD (1994) Low external pH and osmotic shock increase 
the expression of human MDR protein. Biochemistry 33:7229–7238
 147. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al 
(1992) Overexpression of a transporter gene in a multidrug‑resistant 
human lung cancer cell line. Science 258:1650–1654
 148. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multid‑
rug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correla‑
tion of protein levels with drug response and messenger RNA levels. 
Clin Cancer Res 7:1798–1804
 149. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG et al 
(2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP 
cellular levels and controls human leukemia cell proliferation and dif‑
ferentiation. J Biol Chem 286:6979–6988
 150. Sauna ZE, Ambudkar SV (2007) About a switch: how P‑glycoprotein 
(ABCB1) harnesses the energy of ATP binding and hydrolysis to do 
mechanical work. Mol Cancer Ther 6:13–23
 151. Keppler D, Leier I, Jedlitschky G, König J (1998) ATP‑dependent trans‑
port of glutathione S‑conjugates by the multidrug resistance protein 
MRP1 and its apical isoform MRP2. Chem Biol Interact 111–112:153–161
 152. Keppler D (1999) Export pumps for glutathione S‑conjugates. Free 
Radic Biol Med 27:985–991
 153. Coley HM (2008) Mechanisms and strategies to overcome chemother‑
apy resistance in metastatic breast cancer. Cancer Treat Rev 34:378–390
 154. Cole SPC, Deeley RG (2006) Transport of glutathione and glutathione 
conjugates by MRP1. Trends Pharmacol Sci 27:438–446
 155. Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new 
understanding of multidrug resistance systems, their properties and 
clinical significance. Cell Mol Life Sci 58:931–959
 156. Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV (2001) The 
mechanism of action of multidrug‑resistance‑linked P‑glycoprotein. J 
Bioenerg Biomembr 33:481–491
 157. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC trans‑
porters in drug resistance, metabolism and toxicity. Curr Drug Deliv 
1:27–42
 158. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M (1999) 
Infliximab (chimeric anti‑tumour necrosis factor alpha monoclonal 
antibody) versus placebo in rheumatoid arthritis patients receiving 
concomitant methotrexate: a randomised phase III trial. ATTRACT Study 
Group. Lancet 354:1932–1939
 159. Cress RH, Deaver NL (1964) Methotrexate in the management of severe 
psoriasis and arthritis: report of a case. South Med J 57:1088–1090
 160. Dale J, Alcorn N, Capell H, Madhok R (2007) Combination therapy for 
rheumatoid arthritis: methotrexate and sulfasalazine together or with 
other DMARDs. Nat Clin Pract Rheumatol 3:450–458 quiz, following 
478
 161. Curt GA, Carney DN, Cowan KH, Jolivet J, Bailey BD, Drake JC et al (1983) 
Unstable methotrexate resistance in human small‑cell carcinoma asso‑
ciated with double minute chromosomes. N Engl J Med 308:199–202
 162. Schimke RT (1984) Gene amplification, drug resistance, and cancer. 
Cancer Res 44:1735–1742
 163. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M 
et al (2005) EGFR mutation and resistance of non‑small‑cell lung cancer 
to gefitinib. N Engl J Med 352:786–792
 164. Longley DB, Harkin DP, Johnston PG (2003) 5‑fluorouracil: mechanisms 
of action and clinical strategies. Nat Rev Cancer 3:330–338
 165. Watson RG, Muhale F, Thorne LB, Yu J, O’Neil BH, Hoskins JM et al (2010) 
Amplification of thymidylate synthetase in metastatic colorectal cancer 
patients pretreated with 5‑fluorouracil‑based chemotherapy. Eur J 
Cancer 46:3358–3364
 166. Wang T‑L, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G et al (2004) 
Digital karyotyping identifies thymidylate synthase amplification as 
a mechanism of resistance to 5‑fluorouracil in metastatic colorectal 
cancer patients. Proc Natl Acad Sci USA 101:3089–3094
 167. Reshkin SJ, Cardone RA, Harguindey S (2013) Na+‑H+ exchanger, pH 
regulation and cancer. Recent Pat Anticancer Drug Discov 8:85–99
 168. Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as 
a therapeutic strategy. Nat Rev Drug Discov 10:767–777
 169. Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C et al 
(2010) Proton dynamics in cancer. J Transl Med 8:57
 170. Alfarouk KO, Muddathir AK, Shayoub MEA (2011) Tumor acidity as 
evolutionary spite. Cancers (Basel) 3:408–414
 171. Hao N‑B, Lü M‑H, Fan Y‑H, Cao Y‑L, Zhang Z‑R, Yang S‑M (2012) Mac‑
rophages in tumor microenvironments and the progression of tumors. 
Clin Dev Immunol 2012:948098
 172. Correia AL, Bissell MJ (2012) The tumor microenvironment is a domi‑
nant force in multidrug resistance. Drug Resist Updat 15:39–49
 173. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the 
tumor microenvironment. J Magn Reson Imaging 16:430–450
 174. Raghunand N, Gillies RJ (2000) pH and drug resistance in tumors. Drug 
Resist Updat 3:39–47
 175. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ (2011) Drug resist‑
ance and cellular adaptation to tumor acidic pH microenvironment. 
Mol Pharm 8:2032–2038
 176. Raghunand N, Mahoney BP, Gillies RJ (2003) Tumor acidity, ion trapping 
and chemotherapeutics. II. pH‑dependent partition coefficients predict 
importance of ion trapping on pharmacokinetics of weakly basic 
chemotherapeutic agents. Biochem Pharmacol 66:1219–1229
 177. Gong Y, Duvvuri M, Krise JP (2003) Separate roles for the Golgi appa‑
ratus and lysosomes in the sequestration of drugs in the multidrug‑
resistant human leukemic cell line HL‑60. J Biol Chem 278:50234–50239
 178. Parkins CS, Chadwick JA, Chaplin DJ (1996) Inhibition of intracellular pH 
control and relationship to cytotoxicity of chlorambucil and vinblastine. 
Br J Cancer Suppl 27:S75–S77
 179. Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HHB et al (2014) 
Glycolysis, tumor metabolism, cancer growth and dissemination. A new 
pH‑based etiopathogenic perspective and therapeutic approach to an 
old cancer question. Oncoscience 1:777–802
 180. Harguindey S, Pedraz JL, García Cañero R, Pérez de Diego J, Cragoe 
EJ (1995) Hydrogen ion‑dependent oncogenesis and parallel new 
avenues to cancer prevention and treatment using a H(+)‑mediated 
unifying approach: pH‑related and pH‑unrelated mechanisms. Crit Rev 
Oncog 6:1–33
 181. Harguindey S, Arranz JL, Polo Orozco JD, Rauch C, Fais S, Cardone RA 
et al (2013) Cariporide and other new and powerful NHE1 inhibitors 
as potentially selective anticancer drugs—an integral molecular/
biochemical/metabolic/clinical approach after 100 years of cancer 
research. J Transl Med 11:282
 182. Van Meir E (1996) Hypoxia‑mediated selection of cells with diminished 
apoptotic potential to solid tumours. Neurosurgery 39:878–879
 183. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB et al 
(2007) Cellular adaptations to hypoxia and acidosis during somatic 
evolution of breast cancer. Br J Cancer 97:646–653
 184. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al 
(1996) Hypoxia‑mediated selection of cells with diminished apoptotic 
potential in solid tumours. Nature 379:88–91
 185. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M (1998) A new role 
for hypoxia in tumor progression: induction of fragile site triggering 
genomic rearrangements and formation of complex DMs and HSRs. 
Mol Cell 2:259–265
Page 12 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
 186. Vaupel P (2004) The role of hypoxia‑induced factors in tumor progres‑
sion. Oncologist 9(Suppl 5):10–17
 187. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on 
human cancer. Nat Rev Cancer 8:967–975
 188. Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM 
(1991) Hypoxia‑induced drug resistance: comparison to P‑glycoprotein‑
associated drug resistance. Br J Cancer 64:809–814
 189. Mattern J, Volm M (1998) Role of oxygenation and vascularization in 
drug resistance. Cytotechnology 27:249–256
 190. Suzuki Y, Tanaka K, Neghishi D, Shimizu M, Murayama N, Hashimoto T 
et al (2008) Increased distribution of carboplatin, an anti‑cancer agent, 
to rat brains with the aid of hyperbaric oxygenation. Xenobiotica 
38:1471–1475
 191. Lara PC, Lloret M, Clavo B, Apolinario RM, Henríquez‑Hernández LA, 
Bordón E et al (2009) Severe hypoxia induces chemo‑resistance in clini‑
cal cervical tumors through MVP over‑expression. Radiat Oncol 4:29
 192. Kim JW, Ho WJ, Wu BM (2011) The role of the 3D environment in 
hypoxia‑induced drug and apoptosis resistance. Anticancer Res 
31:3237–3245
 193. Cosse J‑P, Michiels C (2008) Tumour hypoxia affects the responsiveness 
of cancer cells to chemotherapy and promotes cancer progression. 
Anticancer Agents Med Chem 8:790–797
 194. Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX (2005) Involve‑
ment of hypoxia‑inducible factor‑1‑alpha in multidrug resistance 
induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 24:565–574
 195. Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D et al (2009) Drug‑
metabolising enzymes are down‑regulated by hypoxia in differentiated 
human hepatoma HepaRG cells: HIF‑1alpha involvement in CYP3A4 
repression. Eur J Cancer 45:2882–2892
 196. Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH (2008) 
Hypoxia‑induced resistance to anticancer drugs is associated with 
decreased senescence and requires hypoxia‑inducible factor‑1 activity. 
Mol Cancer Ther 7:1961–1973
 197. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribu‑
tion of the anticancer drug Doxorubicin in relation to blood vessels in 
solid tumors. Clin Cancer Res 11(24 Pt 1):8782–8788
 198. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. 
Nat Rev Cancer 6:583–592
 199. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov 
AV, Blagosklonny MV (2012) Hypoxia suppresses conversion from 
proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 
109:13314–13318
 200. Warburg O (1956) On the origin of cancer cells. Science 123:309–314
 201. Weinhouse S (1956) On respiratory impairment in cancer cells. Science 
124:267–269
 202. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycoly‑
sis? Nat Rev Cancer 4:891–899
 203. Williams B, Howard RL (1994) Glucose‑induced changes in Na+/
H+ antiport activity and gene expression in cultured vascular smooth 
muscle cells. Role of protein kinase C. J Clin Invest 93:2623–2631
 204. Fu Y, Lee AS (2006) Glucose regulated proteins in cancer progression, 
drug resistance and immunotherapy. Cancer Biol Ther 5:741–744
 205. Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE (1988) Glucose 
metabolism in drug‑sensitive and drug‑resistant human breast cancer 
cells monitored by magnetic resonance spectroscopy. Cancer Res 
48:870–877
 206. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P et al (2007) Glucose 
uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes 
drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495–505
 207. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin‑Mon‑
talvo A et al (2012) Fasting cycles retard growth of tumors and sensitize 
a range of cancer cell types to chemotherapy. Sci Transl Med 4:124ra27
 208. Komurov K, Tseng J‑T, Muller M, Seviour EG, Moss TJ, Yang L et al (2012) 
The glucose‑deprivation network counteracts lapatinib‑induced toxic‑
ity in resistant ErbB2‑positive breast cancer cells. Mol Syst Biol 8:596
 209. Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid 
tumors perfused ex vivo: effects of tumor size and perfusion pressure. 
Cancer Res 49:3506–3512
 210. Weiss L, Tveit E, Hultborn R (1985) Vascular resistance characteristics of 
7,12‑dimethylbenz(a)anthracene‑induced rat mammary tumors and 
normal tissues as studied in vitro. Cancer Res 45:2478–2480
 211. Tveit E, Weiss L, Lundstam S, Hultborn R (1987) Perfusion characteristics 
and norepinephrine reactivity of human renal carcinoma. Cancer Res 
47:4709–4713
 212. Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resist‑
ance and the solid tumor microenvironment. J Natl Cancer Inst 
99:1441–1454
 213. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB 
et al (2003) Lowering of tumor interstitial fluid pressure specifically aug‑
ments efficacy of chemotherapy. FASEB J 17:1756–1758
 214. Késmárky G, Kenyeres P, Rábai M, Tóth K (2008) Plasma viscosity: a 
forgotten variable. Clin Hemorheol Microcirc 39:243–246
 215. Kwon O, Krishnamoorthy M, Cho YI, Sankovic JM, Banerjee RK (2008) 
Effect of blood viscosity on oxygen transport in residual stenosed artery 
following angioplasty. J Biomech Eng 130:011003
 216. Stetler‑Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell inter‑
actions with the extracellular matrix during invasion and metastasis. 
Annu Rev Cell Biol 9:541–573
 217. Aoudjit F, Vuori K (2012) Integrin Signaling in Cancer Cell Survival and 
Chemoresistance. Chemother Res Pract 1–16
 218. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000) Role of 
extracellular matrix assembly in interstitial transport in solid tumors. 
Cancer Res 60:2497–2503
 219. Rintoul RC, Sethi T (2001) The role of extracellular matrix in small‑cell 
lung cancer. Lancet Oncol 2:437–442
 220. Rintoul RC, Sethi T (2002) Extracellular matrix regulation of drug resist‑
ance in small‑cell lung cancer. Clin Sci (Lond) 102:417–424
 221. Naci D, El Azreq M‑A, Chetoui N, Lauden L, Sigaux F, Charron D et al 
(2012) α2β1 integrin promotes chemoresistance against doxorubicin 
in cancer cells through extracellular signal‑regulated kinase (ERK). J Biol 
Chem 287:17065–17076
 222. Haslam IS, Jones K, Coleman T, Simmons NL (2008) Induction of 
P‑glycoprotein expression and function in human intestinal epithelial 
cells (T84). Biochem Pharmacol 76:850–861
 223. Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates 
of P‑glycoprotein and cytochrome P4503A coordinately up‑regulate 
these proteins in human colon carcinoma cells. Mol Pharmacol 
49:311–318
 224. Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M 
(2001) Pharmacokinetic interaction of cytochrome P450 3A‑related 
compounds with rhodamine 123, a P‑glycoprotein substrate, in rats 
pretreated with dexamethasone. Drug Metab Dispos 29:145–151
 225. Aquilante CL, Letrent SP, Pollack GM, Brouwer KL (2000) Increased brain 
P‑glycoprotein in morphine tolerant rats. Life Sci 66:47–51
 226. El Hafny B, Chappey O, Piciotti M, Debray M, Boval B, Roux F (1997) 
Modulation of P‑glycoprotein activity by glial factors and retinoic acid 
in an immortalized rat brain microvessel endothelial cell line. Neurosci 
Lett 236:107–111
 227. Dürr D, Stieger B, Kullak‑Ublick GA, Rentsch KM, Steinert HC, Meier PJ 
et al (2000) St John’s Wort induces intestinal P‑glycoprotein/MDR1 and 
intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604
 228. Jonsson O, Behnam‑Motlagh P, Persson M, Henriksson R, Grankvist K 
(1999) Increase in doxorubicin cytotoxicity by carvedilol inhibition of 
P‑glycoprotein activity. Biochem Pharmacol 58:1801–1806
 229. Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Méria P et al 
(2006) Role of P‑glycoprotein in cyclosporine cytotoxicity in the 
cyclosporine‑sirolimus interaction. Kidney Int 70:1019–1025
 230. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K 
(1999) Cellular pharmacokinetic aspects of reversal effect of itracona‑
zole on P‑glycoprotein‑mediated resistance of anticancer drugs. Biol 
Pharm Bull 22:1355–1359
 231. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW et al (1997) 
Tacrolimus oral bioavailability doubles with coadministration of keto‑
conazole. Clin Pharmacol Ther 62:41–49
 232. Callaghan R, Riordan JR (1993) Synthetic and natural opiates inter‑
act with P‑glycoprotein in multidrug‑resistant cells. J Biol Chem 
268:16059–16064
 233. Callaghan R, Higgins CF (1995) Interaction of tamoxifen with the multi‑
drug resistance P‑glycoprotein. Br J Cancer 71:294–299
 234. Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YKK et al 
(2006) Tamoxifen paradoxically decreases paclitaxel deposition into 
cerebrospinal fluid of brain tumor patients. J Neurooncol 76:85–92
Page 13 of 13Alfarouk et al. Cancer Cell Int  (2015) 15:71 
 235. Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S (2012) Inhibi‑
tion of P‑glycoprotein functionality by vandetanib may reverse cancer 
cell resistance to doxorubicin. Eur J Pharm Sci 46:484–491
 236. Xu H‑B, Li L, Fu J, Mao X‑P, Xu L‑Z (2012) Reversion of multidrug resist‑
ance in a chemoresistant human breast cancer cell line by β‑elemene. 
Pharmacology 89:303–312
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
